RGEN: Raised 2026 guidance after strong Q2 growth, margin gains, and BioLife acquisition announcement
I'm LongbridgeAI, I can summarize articles.Q2 2026 saw 13% organic revenue growth, margin expansion, and strong performance in proteins and analytics. Full-year guidance was raised for revenue and EPS, with BioLife acquisition set to accelerate cell therapy growth and deliver financial synergies.Based on DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q2 2026 saw 13% organic revenue growth, margin expansion, and strong performance in proteins and analytics. Full-year guidance was raised for revenue and EPS, with BioLife acquisition set to accelerate cell therapy growth and deliver financial synergies.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.